Saturday 17 October 2026
Export A’s income statement to Excel — free account
Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
172.96
2.59
−1.48%
Follow A
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to October
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 34.15 | 45.74 | 60.42 | 62.00 | 61.13 | 112.47 | 112.52 | 96.80 | 124.16 | 96.43 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 48.63 | 70.93 | 75.11 | 85.68 | 120.24 | 179.57 | 160.26 | 159.59 | 155.35 | 160.27 | |||||
| People | |||||||||||||||
| People | Employees | 12,500 | 13,500 | 14,800 | 16,300 | 16,400 | 17,000 | 18,100 | 18,100 | 17,900 | 18,100 | ||||
| Revenue/emp, $m | 0.34 | 0.33 | 0.33 | 0.32 | 0.33 | 0.37 | 0.38 | 0.38 | 0.36 | 0.38 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 4,202 | 4,472 | 4,914 | 5,163 | 5,339 | 6,319 | 6,848 | 6,833 | 6,510 | 6,948 | ||||
| Gross margin, % | 52.28 | 53.64 | 54.54 | 54.33 | 53.14 | 53.92 | 54.35 | 50.71 | 54.30 | 52.43 | |||||
| EBT | 544 | 803 | 946 | 919 | 842 | 1,360 | 1,504 | 1,339 | 1,521 | 1,435 | |||||
| EBT margin, % | 12.95 | 17.96 | 19.25 | 17.80 | 15.77 | 21.52 | 21.96 | 19.60 | 23.36 | 20.65 | |||||
| Net income | 462 | 684 | 316 | 1,071 | 719 | 1,210 | 1,254 | 1,240 | 1,289 | 1,303 | |||||
| Depreciation | 246 | 212 | 210 | 238 | 308 | 321 | 317 | 271 | 257 | 288 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 12.89 | 13.89 | 15.31 | 16.44 | 17.28 | 20.79 | 22.90 | 23.24 | 22.45 | 24.46 | ||||
| Earnings | 1.41 | 2.12 | 0.98 | 3.41 | 2.33 | 3.98 | 4.19 | 4.22 | 4.44 | 4.59 | |||||
| Cash flow | 2.43 | 2.76 | 3.39 | 3.25 | 2.98 | 4.88 | 4.39 | 6.03 | 6.04 | 5.49 | |||||
| Capex | (0.43) | (0.55) | (0.55) | (0.50) | (0.38) | (0.62) | (0.97) | (1.01) | (1.30) | (1.43) | |||||
| Free cash flow | 2.01 | 2.21 | 2.84 | 2.75 | 2.60 | 4.27 | 3.41 | 5.01 | 4.73 | 4.06 | |||||
| Book value | 13.02 | 15.02 | 14.24 | 15.12 | 15.77 | 17.73 | 17.74 | 19.88 | 20.34 | 23.74 | |||||
| Shares, m | 326 | 322 | 321 | 314 | 309 | 304 | 299 | 294 | 290 | 284 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 30.90 | 31.94 | 64.79 | 22.35 | 45.17 | 39.46 | 32.94 | 24.50 | 29.35 | 31.96 | ||||
| P/S | 3.38 | 4.90 | 4.23 | 4.61 | 6.09 | 7.56 | 6.04 | 4.45 | 5.80 | 5.98 | |||||
| P/B | 3.35 | 4.53 | 4.55 | 5.01 | 6.67 | 8.86 | 7.80 | 5.20 | 6.41 | 6.17 | |||||
| EV/Sales | 3.29 | 4.70 | 4.14 | 4.69 | 6.25 | 7.74 | 6.29 | 4.62 | 6.11 | 6.16 | |||||
| EV/FCF | 21.13 | 29.49 | 22.34 | 27.94 | 41.55 | 37.76 | 42.29 | 21.44 | 29.06 | 37.11 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 793 | 889 | 1,087 | 1,021 | 921 | 1,485 | 1,312 | 1,772 | 1,751 | 1,559 | ||||
| Capex | (139) | (176) | (176) | (156) | (118) | (188) | (291) | (298) | (378) | (407) | |||||
| Free cash flow | 654 | 713 | 911 | 865 | 803 | 1,297 | 1,021 | 1,474 | 1,373 | 1,152 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2,690 | 2,906 | 2,677 | 1,109 | 1,948 | 2,091 | 1,917 | 2,583 | 2,064 | 2,247 | ||||
| Total debt | 1,904 | 1,801 | 1,799 | 1,791 | 2,284 | 2,729 | 2,733 | 2,735 | 3,345 | 3,050 | |||||
| Net debt | (385) | (877) | (448) | 409 | 843 | 1,154 | 1,680 | 1,145 | 2,016 | 1,261 | |||||
| Shareholders’ equity | 4,246 | 4,835 | 4,571 | 4,748 | 4,873 | 5,389 | 5,305 | 5,845 | 5,898 | 6,741 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 6.05 | 8.43 | 3.72 | 11.90 | 7.54 | 11.90 | 11.81 | 11.65 | 11.40 | 10.61 | ||||
| ROIC | 9.96 | 12.74 | 13.70 | 11.40 | 9.25 | 12.87 | 14.48 | 12.07 | 11.75 | 11.55 | |||||
| ROE | 10.98 | 15.06 | 6.72 | 22.99 | 14.95 | 23.58 | 23.45 | 22.24 | 21.95 | 20.62 | |||||
Negative figures in brackets.
Fiscal years to Oct 2025 · latest quarter Jul 2026
Charts ten years each
Agilent Technologies, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NTRA Natera, Inc. | $58.4B | — (loss-making) | — (loss-making) | +37.71% (above 0%: growing) | n/m | −173.96% (below 0%: shrinking) | 64.46% | (10.07%) | Compare |
| A Agilent Technologies, Inc. | $49.5B | 34.0× | 26.3× | +8.06% (above 0%: growing) | +8.47% (above 0%: growing) | +69.50% (above 0%: growing) | 55.48% | 23.64% | |
| IQV IQVIA Holdings Inc. | $44.6B | 32.8× | 22.3× | +8.74% (above 0%: growing) | −0.65% (below 0%: shrinking) | +23.29% (above 0%: growing) | 32.85% | 11.58% | Compare |
| WAT Waters Corporation | $43.6B | 109× | 44.3× | +113.36% (above 0%: growing) | n/m | +750.00% (above 0%: growing) | 44.62% | (5.23%) | Compare |
| IDXX IDEXX Laboratories, Inc. | $43.1B | 39.1× | 38.3× | +9.66% (above 0%: growing) | +17.21% (above 0%: growing) | +111.44% (above 0%: growing) | 64.04% | 34.98% | Compare |
| ILMN Illumina, Inc. | $40.5B | 48.4× | 34.7× | +9.44% (above 0%: growing) | −8.05% (below 0%: shrinking) | −18.27% (below 0%: shrinking) | 66.44% | 21.14% | Compare |
| MTD Mettler-Toledo International, Inc. | $32.8B | 36.4× | 25.5× | +4.48% (above 0%: growing) | +18.30% (above 0%: growing) | +33.01% (above 0%: growing) | 63.29% | 30.61% | Compare |
| DGX Quest Diagnostics Incorporated | $26.4B | 24.6× | 20.8× | +10.21% (above 0%: growing) | +14.74% (above 0%: growing) | +5.28% (above 0%: growing) | 33.75% | 15.08% | Compare |
| LH Labcorp Holdings Inc. | $26.4B | 26.2× | 19.0× | +5.78% (above 0%: growing) | +28.42% (above 0%: growing) | −42.01% (below 0%: shrinking) | 29.80% | 12.10% | Compare |
| Median of peers | $41.8B | 36.4× | 25.5× | +9.55% | +15.98% | +14.29% | 53.96% | 13.59% |
A metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Agilent Technologies, Inc. (A) key facts
- Strength: Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.
- Strength: Net income was $1.3 billion, or $4.59 per share (basic), a net margin of 18.8%.
- Agilent Technologies, Inc. (A) is a Diagnostics & Research company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, A traded at $172.96, a market capitalization of $49.5 billion.
- At that price the stock trades at 34.0× trailing-twelve-month earnings and 6.6× sales; its P/E is higher than 66% of its own readings over the past ten years.
- Agilent Technologies, Inc. pays an annual dividend of $1.02 per share, a yield of 0.59%, with a payout ratio of 20.1%.
- Return on equity was 20.6% and debt-to-equity 0.50.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.46 (safe zone) for fiscal 2025.